US Dollar Slips After PCE Inflation Data as Fed Rate Hike Expectations Stay Elevated 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts 
Gold Prices Rise Above $4,000 as Inflation Data and Weaker Dollar Boost Demand 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
South Korea’s KOSPI Jumps Over 5% as Samsung, SK Hynix Rally on Micron Earnings Boost 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
